Orbifloxacin
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
113617-63-3- Standard-SMILES
C[C@@H]1CN(c2c(F)c(F)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@H](C)N1- InChIKey
QIPQASLPWJVQMH-DTORHVGOSA-N- Summenformel
- C19H20F3N3O3
- Durchschnittliche Molmasse
- 395,4 g/mol
- Monoisotopische Masse
- 395,14567599
Namen und Bezeichner
- Bevorzugter Name
- Orbifloxacin
- IUPAC
- 1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid
Namen und Synonyme
ORBIFLOXACIN113617-63-3OrbaxorbifloxacineorbifloxacinoDTXSID7046201NSC-758614660932TPY61-cyclopropyl-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acidorbifloxacinumOrbax TabletsRefChem:57814
Weitere Namen anzeigen
DTXCID9017777861-cyclopropyl-7-((3S,5R)-3,5-dimethylpiperazin-4-ium-1-yl)-5,6,8-trifluoro-4-oxoquinoline-3-carboxylate638-855-2MFCD008648583-Quinolinecarboxylic acid, 1-cyclopropyl-7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5,6,8-trifluoro-1,4-dihydro-4-oxo-, rel-1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acidNCGC00160518-01CP-104354
Datenbank-Bezeichner
- CAS
113617-63-3- PubChem CID
- 60605
- DTXSID
DTXSID7046201- ChEMBL
CHEMBL295433- ChEBI
CHEBI:183823- UNII
- 660932TPY6
- EC Number
- 638-855-2
- Nikkaji
- J323.323E
Eigenschaften
Berechnete StruktureigenschaftenWird ergänzt
- XLogP
- 0,9
- Polarare Oberfläche (TPSA)
- 72,9 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 9
- Frei drehbare Bindungen
- 3
- Schwere Atome
- 28
- Formalladung
- 0
- Komplexität
- 691
Experimentelle und physikochemische Eigenschaften
Collision Cross Section
196.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
206.1 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]；199.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]
199.41 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]；184.66 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 46 reports by companies from 2 notifications to the ECHA C&L Inventory.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Gefahrenhinweise
Regulatory InformationOrbifloxacin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesRepr. 2 (100%)
Regulatorische Informationen
Regulatory InformationOrbifloxacin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Chemie und Industrie
Pharmakologische Informationen
ATC CodeQJ - Antiinfectives for systemic use；QJ01 - Antibacterials for systemic use；QJ01M - Quinolone and quinoxaline antibacterials；QJ01MA - Fluoroquinolones；QJ01MA95 - Orbifloxacin
Verwendung und Herstellung
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
Anbieter20 Anbieter
国药集团化学试剂有限公司86-21-63210123 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
大连美仑生物技术有限公司0411-62910999 13889544652 · [email protected]
四川库利南科技有限公司400-1166-196 18981987031 · [email protected]
湖南汇百侍生物科技有限公司0731-85526065 13308475853 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
广州爱纯医药科技有限公司020-39119399 18927568969 · [email protected]
杭州杰恒化工有限公司0571-87396432 · [email protected]
湖北巨胜科技有限公司027-59599241 18871490274 · [email protected]
Zugehörige Reaktionen
1
Notizen zur Verbindung
Wird geladen…